Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
A concise checklist to verify inputs, validate assumptions, and confirm your zero based budget remains aligned with priorities.
17,617 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Institutional moves are reshaping exposure to China as the market resets. This article explains what happened with mi...
On March 2, energy and defense names spearheaded gains as oil jumped, while travel and leisure stocks softened. This ...
Leveraged ETFs promise amplified moves, but they can amplify losses just as quickly. This guide breaks down why lever...
Logan Finance rolls out a premium Open Road Elevated tier to serve high-net-worth borrowers with larger loan needs ou...
Oracle has a booming backlog that signals future revenue, but it also requires massive spending. This article breaks ...
AI is reshaping big tech, but not all bets are the same. This guide weighs Microsoft and Amazon on AI power, cash flo...
Despite a 2026 pullback, Advanced Micro Devices still shows fundamental strength in data-center AI demand and a diver...
Investors on Wall Street are pouring capital into Ukraine's drone technology, led by Swarmers, signaling a new phase ...
Retirement success isn’t about chasing one hot stock. It’s about a well-balanced mix of growth, income, and safety. L...
SkyWater Technology just posted a record revenue figure, but the CFO sold about $2.5 million worth of stock. This art...
Centene's Sarah London, the youngest-ever female Fortune 500 CEO, is steering a bold reinvention of the nation's larg...